Genetic variation in prostaglandin synthesis and related pathways, NSAID use, and colorectal cancer risk in the Colon Cancer Family Registry.

Publication Type:

Journal Article


Carcinogenesis (2014)


2014, June 2014, Public Health Sciences Division


Although use of non-steroidal anti-inflammatory drugs (NSAIDs) generally decreases colorectal cancer (CRC) risk, inherited genetic variation in inflammatory pathways may alter their potential as preventive agents. We investigated whether variation in prostaglandin synthesis and related pathways influences CRC risk in the Colon Cancer Family Registry by examining associations between 192 single nucleotide polymorphisms (SNPs) and two variable nucleotide tandem repeats (VNTRs) within 17 candidate genes and CRC risk. We further assessed interactions between these polymorphisms and NSAID use on CRC risk. Using a case-unaffected-sibling-control design, this study included 1,621 primary invasive CRC cases and 2,592 sibling controls among Caucasian men and women aged 18-90. After adjustment for multiple comparisons, two intronic SNPs were associated with rectal cancer risk: rs11571364 in ALOX12 (ORhet/hzv 1.87, 95% CI 1.19-2.95, p=0.03) and rs45525634 in PTGER2 (ORhet/hzv 0.49, 95% CI 0.29-0.82, p=0.03). Additionally, there was an interaction between NSAID use and the intronic SNP rs2920421 in ALOX12 on risk of CRC (p=0.03); among those with heterozygous genotypes, risk was reduced for current NSAID users compared to never or former users (ORhet 0.60, 95% CI 0.45-0.80), though not among those with homozygous wildtype or variant genotypes. The results of this study suggest that genetic variation in ALOX12 and PTGER2 may affect the risk of rectal cancer. In addition, this study suggests plausible interactions between NSAID use and variants in ALOX12 on CRC risk. These results may aid in the development of genetically targeted cancer prevention strategies with NSAIDs.